drugset / Trial / NCT00692224

Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial

NCT00692224

Phase 1/2 Completed 294 enrolled All India Institute of Medical Sciences
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine the effect of 10 mg of oral zinc given daily between days 2 and 7 of life to term or near term neonates with serum bilirubin levels of more than 6 mg/dL at 24 ± 6 hours of life on hyperbilirubinemia and phototherapy.

Timeline

Start
2005-10
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Zinc gluconate Small molecule 10 mg Oral

Indications

No indication recorded.